TY - JOUR
T1 - Clot composition and recanalization outcomes in mechanical thrombectomy
AU - Nogueira, Raul G.
AU - Pinheiro, Agostinho
AU - Brinjikji, Waleed
AU - Abbasi, Mehdi
AU - Al-Bayati, Alhamza R.
AU - Mohammaden, Mahmoud H.
AU - Souza Viana, Lorena
AU - Ferreira, Felipe
AU - Abdelhamid, Hend
AU - Bhatt, Nirav R.
AU - Kvamme, Peter
AU - Layton, Kennith F.
AU - Delgado Almandoz, Josser E.
AU - Hanel, Ricardo A.
AU - Mendes Pereira, Vitor
AU - Almekhlafi, Mohammed A.
AU - Yoo, Albert J.
AU - Jahromi, Babak S.
AU - Gounis, Matthew J.
AU - Patel, Biraj
AU - Arturo Larco, Jorge L.
AU - Fitzgerald, Sean
AU - Mereuta, Oana Madalina
AU - Doyle, Karen
AU - Savastano, Luis E.
AU - Cloft, Harry J.
AU - Thacker, Ike C.
AU - Kayan, Yasha
AU - Copelan, Alexander
AU - Aghaebrahim, Amin
AU - Sauvageau, Eric
AU - Demchuk, Andrew M.
AU - Bhuva, Parita
AU - Soomro, Jazba
AU - Nazari, Pouya
AU - Cantrell, Donald Robert
AU - Puri, Ajit S.
AU - Entwistle, John
AU - Polley, Eric C.
AU - Frankel, Michael R.
AU - Kallmes, David F.
AU - Haussen, Diogo C.
N1 - Funding Information:
RGN reported consulting fees for advisory roles with Anaconda, Biogen, Cerenovus, Genentech, Hybernia, Imperative Care, Medtronic, Phenox, Philips, Prolong Pharmaceuticals, Stryker Neurovascular, Shanghai Wallaby, and Synchron and stock options for advisory roles with Astrocyte, Brainomix, Cerebrotech, Ceretrieve, Corindus Vascular Robotics, Vesalio, Viz-AI, RapidPulse, and Perfuze, and investments in Viz-AI, Perfuze, Cerebrotech, Reist/Q’Apel Medical, Truvic, and Viseon. WB is a consulting medical director for MIVI Neurovascular, consultant for Cerenovus, Microvention, Stryker, Medtronic, Imperative Care and receives research funding from Cerenovus, Brainomix, NIH. ARA-B is a consultant for Stryker Neurovascular. RAH is a consultant for Stryker, Medtronic, Cerenovous, Microvention, Balt, Phenox, Rapid Medical, and Q’Apel. He is on the advisory board for MiVI, eLum, Three Rivers, Shape Medical, and Corindus. AJY receives grants from Medtronic, Cerenovus, Penumbra, Stryker, and Penumbra. He is a consultant for Cerenovus, Penumbra, Vesalio, Zoll, Philips, Rapid Medical, and StrokeNet (MOST trial). AJY also has equity interest in Insera Therapeutics and Nicolab. MJG has been a consultant on a fee-per-hour basis for Alembic LLC, Astrocyte Pharmaceuticals, BendIt Technologies, Cerenovus, Imperative Care, the Jacob’s Institute, Medtronic Neurovascular, Mentice, Mivi Neurosciences, phenox GmbH, Q’Apel, Route 92 Medical, Scientia, Stryker, Wallaby Medical; holds stock in Imperative Care, InNeuroCo, Galaxy Therapeutics and Neurogami; and has received research support from the National Institutes of Health (NIH), the United States – Israel Binational Science Foundation, Anaconda, ApicBio, Arsenal Medical, Axovant, Balt, Cerenovus, Ceretrieve, CereVasc LLC, Cook Medical, Galaxy Therapeutics, Gentuity, Gilbert Foundation, Imperative Care, InNeuroCo, Insera, Jacob’s Institute, Magneto, Microvention, Medtronic Neurovascular, MIVI Neurosciences, Naglreiter MDDO, Neurogami, Philips Healthcare, Progressive Medical, Pulse Medical, Rapid Medical, Route 92 Medical, Scientia, Stryker Neurovascular, Syntheon, ThrombX Medical, Wallaby Medical, the Wyss Institute and Xtract Medical. KD is supported by a grant from Science Foundation Ireland (SFI) and the European Regional Development Fund (ERDF) under grant number 13/RC/2073_P2. ASP is a consultant for Medtronic Neurovascular, Stryker Neurovascular, Balt, Q’Apel Medical, Cerenovus, Microvention, Imperative Care, Agile, Merit, CereVasc and Arsenal Medical and receives research grants from NIH, Microvention. DCH is a consultant for Stryker,Cerenovus and is a member of the Data and Safety Monitoring Board for Vesalio and Jacobs Institute. He also holds stock options of VizAI. The other authors have no competing interests to disclose.
Publisher Copyright:
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
PY - 2023
Y1 - 2023
N2 - Background: Mechanical thrombectomy (MT) has become standard for large vessel occlusions, but rates of complete recanalization are suboptimal. Previous reports correlated radiographic signs with clot composition and a better response to specific techniques. Therefore, understanding clot composition may allow improved outcomes. Methods: Clinical, imaging, and clot data from patients enrolled in the STRIP Registry from September 2016 to September 2020 were analyzed. Samples were fixed in 10% phosphate-buffered formalin and stained with hematoxylin-eosin and Martius Scarlett Blue. Percent composition, richness, and gross appearance were evaluated. Outcome measures included the rate of first-pass effect (FPE, modified Thrombolysis in Cerebral Infarction 2c/3) and the number of passes. Results: A total of 1430 patients of mean±SD age 68.4±13.5 years (median (IQR) baseline National Institutes of Health Stroke Scale score 17.2 (10.5-23), IV-tPA use 36%, stent-retrievers (SR) 27%, contact aspiration (CA) 27%, combined SR+CA 43%) were included. The median (IQR) number of passes was 1 (1-2). FPE was achieved in 39.3% of the cases. There was no association between percent histological composition or clot richness and FPE in the overall population. However, the combined technique resulted in lower FPE rates for red blood cell (RBC)-rich (P<0.0001), platelet-rich (P=0.003), and mixed (P<0.0001) clots. Fibrin-rich and platelet-rich clots required a higher number of passes than RBC-rich and mixed clots (median 2 and 1.5 vs 1, respectively; P=0.02). CA showed a trend towards a higher number of passes with fibrin-rich clots (2 vs 1; P=0.12). By gross appearance, mixed/heterogeneous clots had lower FPE rates than red and white clots. Conclusions: Despite the lack of correlation between clot histology and FPE, our study adds to the growing evidence supporting the notion that clot composition influences recanalization treatment strategy outcomes.
AB - Background: Mechanical thrombectomy (MT) has become standard for large vessel occlusions, but rates of complete recanalization are suboptimal. Previous reports correlated radiographic signs with clot composition and a better response to specific techniques. Therefore, understanding clot composition may allow improved outcomes. Methods: Clinical, imaging, and clot data from patients enrolled in the STRIP Registry from September 2016 to September 2020 were analyzed. Samples were fixed in 10% phosphate-buffered formalin and stained with hematoxylin-eosin and Martius Scarlett Blue. Percent composition, richness, and gross appearance were evaluated. Outcome measures included the rate of first-pass effect (FPE, modified Thrombolysis in Cerebral Infarction 2c/3) and the number of passes. Results: A total of 1430 patients of mean±SD age 68.4±13.5 years (median (IQR) baseline National Institutes of Health Stroke Scale score 17.2 (10.5-23), IV-tPA use 36%, stent-retrievers (SR) 27%, contact aspiration (CA) 27%, combined SR+CA 43%) were included. The median (IQR) number of passes was 1 (1-2). FPE was achieved in 39.3% of the cases. There was no association between percent histological composition or clot richness and FPE in the overall population. However, the combined technique resulted in lower FPE rates for red blood cell (RBC)-rich (P<0.0001), platelet-rich (P=0.003), and mixed (P<0.0001) clots. Fibrin-rich and platelet-rich clots required a higher number of passes than RBC-rich and mixed clots (median 2 and 1.5 vs 1, respectively; P=0.02). CA showed a trend towards a higher number of passes with fibrin-rich clots (2 vs 1; P=0.12). By gross appearance, mixed/heterogeneous clots had lower FPE rates than red and white clots. Conclusions: Despite the lack of correlation between clot histology and FPE, our study adds to the growing evidence supporting the notion that clot composition influences recanalization treatment strategy outcomes.
KW - Device
KW - Stroke
KW - Thrombectomy
UR - http://www.scopus.com/inward/record.url?scp=85165304800&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85165304800&partnerID=8YFLogxK
U2 - 10.1136/jnis-2023-020117
DO - 10.1136/jnis-2023-020117
M3 - Article
C2 - 37419694
AN - SCOPUS:85165304800
SN - 1759-8478
JO - Journal of neurointerventional surgery
JF - Journal of neurointerventional surgery
M1 - jnis-2023-020117
ER -